Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-06-14
2010-06-22
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S375000, C435S377000, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07741304
ABSTRACT:
The invention provides for antisense oligonucleotides that hybridize to casein kinase 2 nucleic acid sequences and methods of using such antisense oligonucleotides to inhibit expression of casein kinase 2 and reduce the size of solid tumors.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4981863 (1991-01-01), Kane et al.
patent: 5214136 (1993-05-01), Lin et al.
patent: 5218105 (1993-06-01), Cook et al.
patent: 5235033 (1993-08-01), Summerton et al.
patent: 5359044 (1994-10-01), Cook et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5539082 (1996-07-01), Nielsen et al.
patent: 5596086 (1997-01-01), Matteucci et al.
patent: 5602240 (1997-02-01), De Mesmaeker et al.
patent: 5750666 (1998-05-01), Caruthers et al.
patent: 6440738 (2002-08-01), Wyatt
patent: 6455307 (2002-09-01), McKay et al.
patent: 6607916 (2003-08-01), Freier et al.
patent: 6632671 (2003-10-01), Unger
patent: 2002/0147163 (2002-10-01), McKay et al.
patent: 2004/0038303 (2004-02-01), Unger
patent: 2007/0219148 (2007-09-01), Schaack et al.
patent: 2008/0220072 (2008-09-01), Unger et al.
patent: 1 911 451 (2008-04-01), None
patent: WO 02/24950 (2002-03-01), None
patent: WO 03/87389 (2003-10-01), None
Faust et al., “Antisense Oligonucleotides Against Protein Kinase CK2-Alpha Inhibit Growth of Squamous Cell Carcinoma of The Head and Neck In Vitro,”Head and Neck, 2000, 22(4):341-346.
Unger et al., “Protein kinase CK2 as regulator of cell survival: Implications for cancer therapy,”Current Cancer Drug Targets, 2004, 4:77-84.
Unger et al., “Antisense formulation via sub-50nm nanoencapsulation enhances effective . . . ”Proc. 94thAnnual Meeting of American Association for Cancer Research, Jul. 11-14, 2003, p. 1287.
GenBank Accession NM—001320 dated Dec. 23, 2007, 4 pages.
GenBank Accession NM—001892 dated Dec. 23, 2007, 5 pages.
GenBank Accession NM—009974 dated Jan. 9, 2008, 4 pages.
GenBank Accession S72393 dated Jan. 24, 1995, 7 pages.
GenBank Accession X69951 dated Nov. 14, 2006, 8 pages.
GenBank Accession X70251 dated Nov. 10, 2005, 2 pages.
Aukhil et al., “Cell- and Heparin-binding Domains of the Hexabrachion Arm Identified by Tenascin Expression Proteins,”J. Biol Chem., 1993, 268(4):2542-2553.
Cullen, “Enhancing and confirming the specificity of RNAi experiments,”Nature Methods, 2006, 3(9):677-681.
Faust et al., “Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells,”Int. J. Biochem. Cell Biol., 1999, 31:941-949.
Guerra et al., “The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation,”Oncogene, 1997, 14:2683-2688.
Nastainczyk et al., “Isolation and Characterization of a Monoclonal Anti-Protein Kinase CK2 β-Subunit Antibody of the IgG Class for the Direct Detection of CK2 β-Subunit in Tissue Cultures of Various Mammalian Species and Human Tumors,”Hybridoma, 1995, 14(4):335-339.
Nielsen et al., “Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide,”Science, 1991, 254:1497-1500.
Pashley and Karaman, “Surfactants and Self-Assembly” and “Emulsions and Microemulsions,”Applied Colloid and Surface Chemistry, 2004, John Wiley, Chapters 4 and 5, p. 60-85.
Pei and Tuschl, “On the art of identifying effective and specific siRNAs,”Nature Methods, 2006, 3(9):670-676.
Pouton et al., “Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids,”J. Controlled Release, 1998, 53:289-299.
Rolland, “From Genes to Gene Medicines: Recent Advances in Nonviral Gene Delivery,”Crit. Rev. Therapeutic Drug Carr. Syst., 1998, 15(2):143-198.
Sanghvi, “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides,”Antisense Research and Applications, 1993, CRC Press, Boca Raton, FL, Chapter 15, pp. 273-288.
Slaton et al., “Induction of Apoptosis by Antisense CK2 in Human Prostate Cancer Xenograft Model,”Mol. Cancer Res., 2004, 2(12):712-721.
Snøve, Jr. and Rossi, “Expressing short hairpin RNAs in vivo,”Nature Methods, 2006, 3(9):689-695.
Tawfic et al., “Protein kinase CK2 signal in neoplasia,”Histol. Histopathol., 2001, 16:573-582.
Wang et al., “Response of cancer cells to molecular interruption of the CK2 signal,”Mol. Cell. Biochem., 2001, 227:167-174.
Wiznerowicz et al., “Tuning silence: conditional systems for RNA interference,”Nature Methods, 2006, 3(9):682-688.
Ahmad et al., “Targeting CK2 for cancer therapy,”Anti-Cancer Drugs, 2005, 16(10):1037-1043.
Ulloa et al., “Depletion of catalytic and regulatory subunits of protein kinase CK2 by antisense oligonucleotide treatment of neuroblastoma cells,”Cell. Mol. Neurobiol., 1994, 14(5):407-414.
Ahmed Khalil
Davis Alan
Slaton Joel W.
Sloper Dan
Unger Gretchen M.
Fish & Richardson P.C.
McGarry Sean R
Regents of The University of Minnesota
LandOfFree
Casein kinase 2 antisense therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Casein kinase 2 antisense therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Casein kinase 2 antisense therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4185635